Brain-derived Neurotrophic Factor Levels in Pediatric Sickle Cell Disease

Overview

Journal Pediatr Blood Cancer

Specialties Hematology
Oncology
Pediatrics

Date 2019 Nov 19

PMID 31736231

Citations 4

Authors

Eboni I Lance

Emily Barron-Casella

Allen D Everett

James F Casella

Affiliations

Soon will be listed here.

Abstract

Background: Children with sickle cell disease (SCD) have an increased risk of neurological complications, particularly stroke and silent cerebral infarction (SCI). Brain-derived neurotrophic factor (BDNF) is a nerve growth factor associated with neuronal survival, synaptic plasticity, elevated transcranial Doppler (TCD) velocities and increased risk of stroke in patients with SCD. The objective of this study was to analyze plasma BDNF protein levels in children with SCD participating in the Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial (SIT Trial), comparing plasma samples of children with SCD and SCI to plasma samples from children with SCD without SCI, as well as healthy pediatric control participants.

Procedure: Entry, exit, and longitudinal blood samples were collected from 190 SIT Trial participants with SCD and healthy pediatric controls over time. BDNF levels were measured by enzyme-linked immunosorbent assay. Sample collection was not optimized for measurements of BDNF, but factors affecting BDNF levels were accounted for in analyses.

Results: BDNF levels were significantly higher in children with SCD in comparison to healthy pediatric control subjects. BDNF levels significantly increased over time in SCD participants. BDNF levels did not show any significant associations with the presence or absence of SCI or new/progressive SCI/stroke or TCD velocities.

Conclusions: Plasma BDNF levels are elevated and increase over time in children with SCD. Additional studies with more longitudinal samples are needed to address the reasons for those increased levels.

Citing Articles

Circulating biomarkers associated with pediatric sickle cell disease.

Lekpor C, Botchway F, Driss A, Bashi A, Abrahams A, Kusi K Front Mol Biosci. 2025; 11:1481441.

PMID: 39749215 PMC: 11694143. DOI: 10.3389/fmolb.2024.1481441.

Brain-derived neurotrophic factor and neuroimaging in pediatric patients with sickle cell disease.

Mahmoud A, Abd El Naby S, Abdelgawad A, Rizq M, Abd El Hady N Pediatr Res. 2023; 93(7):1922-1926.

PMID: 36774398 PMC: 10313519. DOI: 10.1038/s41390-023-02513-5.

Elevated neuregulin-1 levels correlate with plasma biomarkers of cerebral injury and high stroke risk in children with sickle cell anemia.

Chambliss C, Richardson T, Onyekaba J, Cespedes J, Nti A, Oxendine Harp K Endocr Metab Sci. 2022; 3.

PMID: 35935682 PMC: 9351492. DOI: 10.1016/j.endmts.2021.100088.

Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease.

Lance E, Faulcon L, Fu Z, Yang J, Whyte-Stewart D, Strouse J Proteomics Clin Appl. 2021; 15(5):e2100003.

PMID: 33915030 PMC: 8666096. DOI: 10.1002/prca.202100003.

References

Chen A, Xiong L, Tong Y, Mao M . The neuroprotective roles of BDNF in hypoxic ischemic brain injury. Biomed Rep. 2014; 1(2):167-176. PMC: 3956206. DOI: 10.3892/br.2012.48. View

Casella J, King A, Barton B, White D, Noetzel M, Ichord R . Design of the silent cerebral infarct transfusion (SIT) trial. Pediatr Hematol Oncol. 2010; 27(2):69-89. PMC: 5572477. DOI: 10.3109/08880010903360367. View

Ware R, Davis B, Schultz W, Brown R, Aygun B, Sarnaik S . Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2015; 387(10019):661-670. PMC: 5724392. DOI: 10.1016/S0140-6736(15)01041-7. View

DeBaun M, Gordon M, McKinstry R, Noetzel M, White D, Sarnaik S . Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014; 371(8):699-710. PMC: 4195437. DOI: 10.1056/NEJMoa1401731. View

Armeanu R, Mokkonen M, Crespi B . Meta-Analysis of BDNF Levels in Autism. Cell Mol Neurobiol. 2016; 37(5):949-954. PMC: 11482231. DOI: 10.1007/s10571-016-0415-7. View

Iughetti L, Casarosa E, Predieri B, Patianna V, Luisi S . Plasma brain-derived neurotrophic factor concentrations in children and adolescents. Neuropeptides. 2011; 45(3):205-11. DOI: 10.1016/j.npep.2011.02.002. View

Mattsson N, Carrillo M, Dean R, Devous Sr M, Nikolcheva T, Pesini P . Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimers Dement (Amst). 2016; 1(4):412-9. PMC: 4879481. DOI: 10.1016/j.dadm.2015.09.001. View

DeBaun M, Sarnaik S, Rodeghier M, Minniti C, Howard T, Iyer R . Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood. 2011; 119(16):3684-90. PMC: 3335377. DOI: 10.1182/blood-2011-05-349621. View

Adams R, Brambilla D . Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005; 353(26):2769-78. DOI: 10.1056/NEJMoa050460. View

10.

Lance E, Casella J, Everett A, Barron-Casella E . Proteomic and biomarker studies and neurological complications of pediatric sickle cell disease. Proteomics Clin Appl. 2014; 8(11-12):813-27. PMC: 4268655. DOI: 10.1002/prca.201400069. View

11.

Sulejczak D, Ziemlinska E, Czarkowska-Bauch J, Nosecka E, Strzalkowski R, Skup M . Focal photothrombotic lesion of the rat motor cortex increases BDNF levels in motor-sensory cortical areas not accompanied by recovery of forelimb motor skills. J Neurotrauma. 2007; 24(8):1362-77. DOI: 10.1089/neu.2006.0261. View

12.

Savage W, Barron-Casella E, Fu Z, Dulloor P, Williams L, Crain B . Plasma glial fibrillary acidic protein levels in children with sickle cell disease. Am J Hematol. 2011; 86(5):427-9. PMC: 3870012. DOI: 10.1002/ajh.21995. View

13.

Korley F, Diaz-Arrastia R, Wu A, Yue J, Manley G, Sair H . Circulating Brain-Derived Neurotrophic Factor Has Diagnostic and Prognostic Value in Traumatic Brain Injury. J Neurotrauma. 2015; 33(2):215-25. PMC: 4722554. DOI: 10.1089/neu.2015.3949. View

14.

Hyacinth H, Adams R, Voeks J, Hibbert J, Gee B . Frequent red cell transfusions reduced vascular endothelial activation and thrombogenicity in children with sickle cell anemia and high stroke risk. Am J Hematol. 2013; 89(1):47-51. PMC: 4070426. DOI: 10.1002/ajh.23586. View

15.

Graham E, Burd I, Everett A, Northington F . Blood Biomarkers for Evaluation of Perinatal Encephalopathy. Front Pharmacol. 2016; 7:196. PMC: 4942457. DOI: 10.3389/fphar.2016.00196. View

16.

Simats A, Garcia-Berrocoso T, Montaner J . Neuroinflammatory biomarkers: From stroke diagnosis and prognosis to therapy. Biochim Biophys Acta. 2015; 1862(3):411-24. DOI: 10.1016/j.bbadis.2015.10.025. View

17.

DeBaun M, Kirkham F . Central nervous system complications and management in sickle cell disease. Blood. 2016; 127(7):829-38. DOI: 10.1182/blood-2015-09-618579. View

18.

Kim B, Winstein C . Can Neurological Biomarkers of Brain Impairment Be Used to Predict Poststroke Motor Recovery? A Systematic Review. Neurorehabil Neural Repair. 2016; 31(1):3-24. DOI: 10.1177/1545968316662708. View

19.

Santos G, Alcantara C, Silva-Couto M, Garcia-Salazar L, Russo T . Decreased Brain-Derived Neurotrophic Factor Serum Concentrations in Chronic Post-Stroke Subjects. J Stroke Cerebrovasc Dis. 2016; 25(12):2968-2974. DOI: 10.1016/j.jstrokecerebrovasdis.2016.08.014. View

20.

Hyacinth H, Gee B, Adamkiewicz T, Adams R, Kutlar A, Stiles J . Plasma BDNF and PDGF-AA levels are associated with high TCD velocity and stroke in children with sickle cell anemia. Cytokine. 2012; 60(1):302-8. PMC: 3429653. DOI: 10.1016/j.cyto.2012.05.017. View